MRVI Valuation

Maravai LifeSciences Holdings Inc

Add to Watchlist

Advanced Chart

2.870

-0.02(-0.692%)1D

MRVI Relative Valuation

MRVI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MRVI is overvalued; if below, it's undervalued.

Historical Valuation

Maravai LifeSciences Holdings Inc (MRVI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.87 is considered Undervalued compared with the five-year average of 1178.09. The fair price of Maravai LifeSciences Holdings Inc (MRVI) is between 3.80 to 6.66 according to relative valuation methord. Compared to the current price of 2.87 USD , Maravai LifeSciences Holdings Inc is Undervalued By 24.39%.

Relative Value

Fair Zone

3.80-6.66

Current Price：2.87

24.39%

Undervalued

-13.23

Trailing

Forward

1838.59

EV/EBITDA

Maravai LifeSciences Holdings Inc. (MRVI) has a current EV/EBITDA of 1838.59. The 5-year average EV/EBITDA is 8.68. The thresholds are as follows: Strongly Undervalued below -112.52, Undervalued between -112.52 and -51.92, Fairly Valued between 69.28 and -51.92, Overvalued between 69.28 and 129.88, and Strongly Overvalued above 129.88. The current Forward EV/EBITDA of 1838.59 falls within the Strongly Overvalued range.

-13.82

EV/EBIT

Maravai LifeSciences Holdings Inc. (MRVI) has a current EV/EBIT of -13.82. The 5-year average EV/EBIT is 56.12. The thresholds are as follows: Strongly Undervalued below -164.81, Undervalued between -164.81 and -54.35, Fairly Valued between 166.59 and -54.35, Overvalued between 166.59 and 277.05, and Strongly Overvalued above 277.05. The current Forward EV/EBIT of -13.82 falls within the Historic Trend Line -Fairly Valued range.

2.87

Maravai LifeSciences Holdings Inc. (MRVI) has a current PS of 2.87. The 5-year average PS is 4.42. The thresholds are as follows: Strongly Undervalued below 0.85, Undervalued between 0.85 and 2.64, Fairly Valued between 6.21 and 2.64, Overvalued between 6.21 and 8.00, and Strongly Overvalued above 8.00. The current Forward PS of 2.87 falls within the Historic Trend Line -Fairly Valued range.

-21.13

P/OCF

Maravai LifeSciences Holdings Inc. (MRVI) has a current P/OCF of -21.13. The 5-year average P/OCF is 12.41. The thresholds are as follows: Strongly Undervalued below -27.18, Undervalued between -27.18 and -7.38, Fairly Valued between 32.21 and -7.38, Overvalued between 32.21 and 52.00, and Strongly Overvalued above 52.00. The current Forward P/OCF of -21.13 falls within the Undervalued range.

-14.12

P/FCF

Maravai LifeSciences Holdings Inc. (MRVI) has a current P/FCF of -14.12. The 5-year average P/FCF is 8.48. The thresholds are as follows: Strongly Undervalued below -74.73, Undervalued between -74.73 and -33.13, Fairly Valued between 50.09 and -33.13, Overvalued between 50.09 and 91.69, and Strongly Overvalued above 91.69. The current Forward P/FCF of -14.12 falls within the Historic Trend Line -Fairly Valued range.

Maravai LifeSciences Holdings Inc (MRVI) has a current Price-to-Book (P/B) ratio of 1.56. Compared to its 3-year average P/B ratio of 2.36 , the current P/B ratio is approximately -33.89% higher. Relative to its 5-year average P/B ratio of 9.02, the current P/B ratio is about -82.69% higher. Maravai LifeSciences Holdings Inc (MRVI) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 6.65%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 7.25% , the current FCF yield is about -100.00% lower.

1.56

P/B

Median3y

2.36

Median5y

9.02

0.00

FCF Yield

Median3y

6.65

Median5y

7.25

Competitors Valuation Multiple

The average P/S ratio for MRVI's competitors is 7.33, providing a benchmark for relative valuation. Maravai LifeSciences Holdings Inc Corp (MRVI) exhibits a P/S ratio of 2.87, which is -60.87% above the industry average. Given its robust revenue growth of -36.15%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MRVI.O

Maravai LifeSciences Holdings Inc

Monte Rosa Therapeutics Inc

Vir Biotechnology Inc

Performance Decomposition

Market capitalization of MRVI decreased by 49.38% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.32 to -3.40.

The secondary factor is the Revenue Growth, contributed -36.15%to the performance.

Overall, the performance of MRVI in the past 1 year is driven by P/E Change. Which is more unsustainable.

-36.15%

65.20M → 41.63M

Revenue Growth

-59.90%

-269.87 → -108.23

Margin Expansion

46.67%

-2.32 → -3.40

P/E Change

-49.38%